Exciting news! My first two published articles in the BioNews publication of BioInnovation South Australia (BioSA) are now online.
One details a soon-to-be-released diagnostic test for chronic myeloid leukaemia:
Adelaide molecular diagnostics company Monoquant Pty Ltd is at the exciting stage of conducting final refinements before rolling out a new clinical test for chronic myeloid leukaemia (CML).
Funded in part by a grant from BioInnovation South Australia (BioSA), a digital polymerase chain reaction (PCR) machine will be used to create technical simplifications for better uptake of the new test in Australian and overseas markets, particularly in the USA.
Monoquant Managing Director Professor Alec Morley said, “While scientifically speaking our approach is already suitable for clinical use, the new PCR machine will allow us to simplify our technique to the point where it can be cost competitive with the current widely used detection test.”
Monoquant’s new test is based around detection of mutant DNA from leukaemia cells in peripheral blood.
To read more, click here.
The other piece describes the growing need for bioanalytical services in Singapore:
Six months after opening up a state-of-the-art bioanalytics laboratory in Singapore, Adelaide company CPR Pharma Services Pty Ltd is confident the move will continue to provide pathways for growth in the Asia-Pacific region and beyond.
The new Singapore facility is more than just a geographical expansion of current services – it opens up a whole new world of business opportunities. The Singapore clinical trials market is expected to grow to over US$166 million by 2015, with more than 80 per cent of trials being of international origin.
“Singapore is a hub to multinational pharmaceutical companies. It has an impressive research environment and a great infrastructure that attracts early stage clinical trials. CPR Pharma Services intends to be a part of the growth,” said CPR Pharma Services CEO, Mr Jason Valentine.
Click on Bionews September/October on this page to see the full stories.